A Controlled Randomized Double-Blind Multi-Center Phase II Study of FOLFOX6 or FOLFIRI Combined With Sorafenib Versus Placebo in Second-Line Metastatic Colorectal Carcinoma.

Trial Profile

A Controlled Randomized Double-Blind Multi-Center Phase II Study of FOLFOX6 or FOLFIRI Combined With Sorafenib Versus Placebo in Second-Line Metastatic Colorectal Carcinoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Jun 2013

At a glance

  • Drugs Sorafenib (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms FOSCO
  • Most Recent Events

    • 04 Jun 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
    • 26 Jan 2013 Status changed from active, no longer recruiting to discontinued as reported by European Clinical Trials Database.
    • 01 Dec 2012 Primary endpoint 'Progression-free-survival-duration' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top